Please use this identifier to cite or link to this item:
Title: EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study.
Authors: Genova, Carlo
Socinski, Mark A
Hozak, Rebecca R
Mi, Gu
Kurek, Raffael
Shahidi, Javad
Paz-Ares, Luis
Thatcher, Nick
Rivard, Christopher J
Varella-Garcia, Marileila
Hirsch, Fred R
Keywords: EGFR;FISH;Non–small cell lung cancer;biomarker;necitumumab
metadata.dc.subject.mesh: Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Carcinoma, Squamous Cell
Gene Dosage
In Situ Hybridization, Fluorescence
Lung Neoplasms
Treatment Outcome
Issue Date: 20-Nov-2017
Abstract: Necitumumab is a monoclonal antibody targeting EGFR. In the SQUIRE trial, the addition of necitumumab to chemotherapy for squamous cell lung cancer significantly improved overall survival (OS) (hazard ratio [HR] = 0.84); in a post hoc analysis, EGFR copy number gain determined by fluorescence in situ hybridization (FISH) showed a trend toward improved OS (HR = 0.70) and progression-free survival (PFS) (HR = 0.71) with the addition of necitumumab. We present the analysis of granular EGFR FISH data from SQUIRE to examine the potential predictive role of high polysomy and gene amplification, as both were included in the FISH-positive category. Available specimens from SQUIRE underwent FISH analysis in a central laboratory, and each sample was evaluated by using the Colorado EGFR scoring criteria. The correlation of granular FISH parameters with clinical outcomes was assessed. Samples were available for 557 of 1093 patients; 208 patients (37.3%) were FISH-positive, including 167 (30.0%) with high polysomy and 41 (7.4%) with gene amplification. In patients with high polysomy, the addition of necitumumab resulted in a statistically significant increase in PFS (6.08 versus 5.13 months [p = 0.044]) and nonstatistically significant increase in OS (12.6 versus 9.5 months [p = 0.133]); among patients with gene amplification, the addition of necitumumab did not significantly improve PFS (7.4 versus 5.6 months; [p = 0.334]) but did improve OS (14.8 versus 7.6 months; [p = 0.033]). EGFR copy number gain by FISH might have a role as a predictive biomarker for necitumumab in squamous cell lung cancer. In our opinion, these data encourage further studies to prospectively evaluate this potential biomarker.
metadata.dc.identifier.doi: 10.1016/j.jtho.2017.11.109
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.